S&P 500   3,148.59 (+1.00%)
DOW   27,999.53 (+1.16%)
QQQ   204.77 (+1.16%)
AAPL   269.49 (+1.47%)
FB   201.25 (+0.94%)
MSFT   151.18 (+0.83%)
GOOGL   1,338.74 (+1.50%)
AMZN   1,745.75 (-0.85%)
CGC   18.51 (-0.48%)
NVDA   212.99 (+1.70%)
MU   48.02 (+3.00%)
BABA   200.16 (+0.08%)
GE   11.01 (+2.04%)
TSLA   337.78 (+1.43%)
T   38.41 (+0.58%)
AMD   39.86 (+0.43%)
ACB   2.43 (-0.82%)
F   9.00 (+0.67%)
PRI   136.22 (+1.43%)
NFLX   304.71 (+0.13%)
BAC   33.75 (+1.99%)
GILD   67.07 (+0.48%)
DIS   147.97 (+0.36%)
S&P 500   3,148.59 (+1.00%)
DOW   27,999.53 (+1.16%)
QQQ   204.77 (+1.16%)
AAPL   269.49 (+1.47%)
FB   201.25 (+0.94%)
MSFT   151.18 (+0.83%)
GOOGL   1,338.74 (+1.50%)
AMZN   1,745.75 (-0.85%)
CGC   18.51 (-0.48%)
NVDA   212.99 (+1.70%)
MU   48.02 (+3.00%)
BABA   200.16 (+0.08%)
GE   11.01 (+2.04%)
TSLA   337.78 (+1.43%)
T   38.41 (+0.58%)
AMD   39.86 (+0.43%)
ACB   2.43 (-0.82%)
F   9.00 (+0.67%)
PRI   136.22 (+1.43%)
NFLX   304.71 (+0.13%)
BAC   33.75 (+1.99%)
GILD   67.07 (+0.48%)
DIS   147.97 (+0.36%)
S&P 500   3,148.59 (+1.00%)
DOW   27,999.53 (+1.16%)
QQQ   204.77 (+1.16%)
AAPL   269.49 (+1.47%)
FB   201.25 (+0.94%)
MSFT   151.18 (+0.83%)
GOOGL   1,338.74 (+1.50%)
AMZN   1,745.75 (-0.85%)
CGC   18.51 (-0.48%)
NVDA   212.99 (+1.70%)
MU   48.02 (+3.00%)
BABA   200.16 (+0.08%)
GE   11.01 (+2.04%)
TSLA   337.78 (+1.43%)
T   38.41 (+0.58%)
AMD   39.86 (+0.43%)
ACB   2.43 (-0.82%)
F   9.00 (+0.67%)
PRI   136.22 (+1.43%)
NFLX   304.71 (+0.13%)
BAC   33.75 (+1.99%)
GILD   67.07 (+0.48%)
DIS   147.97 (+0.36%)
S&P 500   3,148.59 (+1.00%)
DOW   27,999.53 (+1.16%)
QQQ   204.77 (+1.16%)
AAPL   269.49 (+1.47%)
FB   201.25 (+0.94%)
MSFT   151.18 (+0.83%)
GOOGL   1,338.74 (+1.50%)
AMZN   1,745.75 (-0.85%)
CGC   18.51 (-0.48%)
NVDA   212.99 (+1.70%)
MU   48.02 (+3.00%)
BABA   200.16 (+0.08%)
GE   11.01 (+2.04%)
TSLA   337.78 (+1.43%)
T   38.41 (+0.58%)
AMD   39.86 (+0.43%)
ACB   2.43 (-0.82%)
F   9.00 (+0.67%)
PRI   136.22 (+1.43%)
NFLX   304.71 (+0.13%)
BAC   33.75 (+1.99%)
GILD   67.07 (+0.48%)
DIS   147.97 (+0.36%)
Log in

NASDAQ:ATRC - AtriCure Stock Price, Forecast & News

$30.60
+0.92 (+3.10 %)
(As of 12/6/2019 11:32 AM ET)
Today's Range
$29.85
Now: $30.60
$30.60
50-Day Range
$26.07
MA: $28.21
$29.99
52-Week Range
$22.57
Now: $30.60
$33.92
Volume4,076 shs
Average Volume225,991 shs
Market Capitalization$1.21 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.29
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$201.63 million
Book Value$6.47 per share

Profitability

Net Income$-21,140,000.00

Miscellaneous

Employees620
Market Cap$1.21 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.


AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) announced its quarterly earnings data on Wednesday, October, 30th. The medical device company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.03. The medical device company had revenue of $56.60 million for the quarter, compared to analyst estimates of $55.12 million. AtriCure had a negative return on equity of 13.59% and a negative net margin of 10.13%. The firm's revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.24) EPS. View AtriCure's Earnings History.

When is AtriCure's next earnings date?

AtriCure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for AtriCure.

What price target have analysts set for ATRC?

5 equities research analysts have issued 12 month price objectives for AtriCure's shares. Their forecasts range from $30.00 to $40.00. On average, they expect AtriCure's share price to reach $36.20 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for AtriCure.

What is the consensus analysts' recommendation for AtriCure?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

Has AtriCure been receiving favorable news coverage?

Press coverage about ATRC stock has been trending extremely negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AtriCure earned a news sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the medical device company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for AtriCure.

Are investors shorting AtriCure?

AtriCure saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 822,100 shares, a decline of 37.7% from the October 31st total of 1,320,000 shares. Based on an average daily trading volume, of 272,900 shares, the short-interest ratio is currently 3.0 days. Currently, 2.2% of the shares of the company are sold short. View AtriCure's Current Options Chain.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include Amgen (AMGN), AbbVie (ABBV), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Cellectis (CLLS), Intel (INTC), Micron Technology (MU), Abbott Laboratories (ABT) and Allergan (AGN).

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
  • Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
  • Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)

Who are AtriCure's major shareholders?

AtriCure's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (2.53%), GW&K Investment Management LLC (2.50%), Tamarack Advisers LP (2.15%), Peregrine Capital Management LLC (2.08%), Emerald Advisers LLC (1.11%) and Man Group plc (0.83%). Company insiders that own AtriCure stock include Douglas J Seith, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View Institutional Ownership Trends for AtriCure.

Which institutional investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Endurant Capital Management LP, Man Group plc, Eagle Asset Management Inc., Squarepoint Ops LLC, Public Employees Retirement System of Ohio, Emerald Advisers LLC and WCM Investment Management LLC. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade and Michael H Carrel. View Insider Buying and Selling for AtriCure.

Which institutional investors are buying AtriCure stock?

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, GW&K Investment Management LLC, Peregrine Capital Management LLC, Point72 Asset Management L.P., SG Americas Securities LLC, Rice Hall James & Associates LLC, First Trust Advisors LP and California Public Employees Retirement System. View Insider Buying and Selling for AtriCure.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $30.60.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.21 billion and generates $201.63 million in revenue each year. The medical device company earns $-21,140,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. AtriCure employs 620 workers across the globe.View Additional Information About AtriCure.

What is AtriCure's official website?

The official website for AtriCure is http://www.atricure.com/.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  423 (Vote Outperform)
Underperform Votes:  308 (Vote Underperform)
Total Votes:  731
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel